undamentalytics Newsletter
Sign in

ALX Oncology Holdings Inc (ALXO) stock

Add to watchlist

Add holding +

NASDAQ: ALXO Nasdaq Biotechnology Next results ~November 6, 2026

ALX Oncology Holdings Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 3 selling1 purchase and 7 sales by directors and officers, last 12 monthsInsider trades
  • Funds66 adding, 21 cuttingOf 21 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 6, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 32% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 6 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -3694.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -3242.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 459.9% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 63.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 92% and a beta of 0.5 against the S&P 500.

Latest results: FY2020 Q4

Filed March 9, 2023
Earnings per share
-$0.11 against an average estimate of -$0.16: beat by 32.5%
Share reaction
+9.4% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 6, 2026

ALX Oncology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+12.3%
  • 1 week+21.2%
  • 1 month+12.3%
  • This year+21.2%
  • 1 year-11.0%
  • 5 years-97.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-0.93

Growth

Share count change
+63.0%

Earnings

Last results
August 6, 2026
Next results (est.)
November 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

ALX Oncology Holdings Inc valuation models and calculator

No model value for ALX Oncology Holdings Inc at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 6, 2026, before the open. Analysts expect revenue of $0 for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.64 −60% — 0%
Next −$0.55 +3% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −10.6% on 90 days ago. In the last 30 days, 1 analyst raised ALX Oncology Holdings Inc's forecast and 0 cut it.

Consensus EPS forecast ALX Oncology Holdings Inc, last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.95 Current fiscal year, 60 days ago: −$2.65 Current fiscal year, 30 days ago: −$2.65 Current fiscal year, 7 days ago: −$2.65 Current fiscal year, Now: −$2.64 −$2.64 Next fiscal year, 90 days ago: −$0.58 Next fiscal year, 60 days ago: −$0.58 Next fiscal year, 30 days ago: −$0.55 Next fiscal year, 7 days ago: −$0.55 Next fiscal year, Now: −$0.55 −$0.55

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.95−$0.58
60 days ago −$2.65−$0.58
30 days ago −$2.65−$0.55
7 days ago −$2.65−$0.55
Now −$2.64−$0.55

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.16 −$0.11 +32.5%
Mar 2026 −$0.16 −$0.15 +6.8%
Dec 2025 −$0.32 −$0.37 −15.5%
Sept 2025 −$0.37 −$0.41 −10.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy686%
Hold114%
Sell00%

Monthly trend

  1. Oct 20261517
  2. Sep 20261517

Counts of recommendations published by analysts covering ALX Oncology Holdings Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.8%
of tradable shares
Days to cover
3.83
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
94%
of shares
Held by insiders
1.0%
of shares
Employees
48
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ALXO−75%−48%+32%−89%−32%+21%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ALXO33%50%58%33%25%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ALXO−76%−73%−64%−93%−78%−66%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 17, 2020: 100% from December 10, 2020 to June 27, 2025. Getting back needed a 27550% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.90 – $2.60
From 52-week high
−47.3%
vs 50-day average
−8.6%
vs 200-day average
−24.9%
Volatility (1 year)
92%
Beta vs S&P 500
0.52

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±7.1%
After a week
6 up, 6 down
typical move ±15.4%
After a month
6 up, 6 down
typical move ±32.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +9.4% +0.5% +1.0% +4.7%
May 8, 2026 +11.2% +1.1% +8.6% −17.1%
February 27, 2026 −9.8% −0.4% −6.0% −18.7%
November 7, 2025 +7.6% +1.7% +16.9% +24.6%
August 12, 2025 +7.5% +1.4% +44.7% +91.9%
May 8, 2025 −12.8% +0.6% −9.9% +19.6%
March 6, 2025 +1.9% −1.2% −20.1% −50.4%
November 7, 2024 −5.2% +1.2% −13.1% +12.4%
August 8, 2024 +1.6% +2.8% +3.1% −18.3%
May 9, 2024 −2.4% +0.7% −11.7% −47.8%
March 7, 2024 +3.0% +0.4% −24.5% −17.8%
November 13, 2023 +13.2% +1.8% +25.6% +70.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) ALX Oncology Holdings Inc
$0 $2M $4M $6M FY20 Q1 FY20 Q2 FY20 Q3 FY20 Q4 Revenue (TTM), FY20 Q1: $4.4M Revenue (TTM), FY20 Q2: $3.7M Revenue (TTM), FY20 Q3: $2.4M Revenue (TTM), FY20 Q4: $1.2M $1.2M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY20 Q1 $4.4M
FY20 Q2 $3.7M
FY20 Q3 $2.4M
FY20 Q4 $1.2M
Operating margin (TTM) ALX Oncology Holdings Inc
-4000% -3000% -2000% -1000% 0% FY20 Q1 FY20 Q2 FY20 Q3 FY20 Q4 Operating margin (TTM), FY20 Q1: -457.1% Operating margin (TTM), FY20 Q2: -733.9% Operating margin (TTM), FY20 Q3: -1401.7% Operating margin (TTM), FY20 Q4: -3694.0% -3694.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q1 -457.1%
FY20 Q2 -733.9%
FY20 Q3 -1401.7%
FY20 Q4 -3694.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022
Income
Revenue 2 5 1 0 0
EBITDA −13 −19 −43 −84 −127
Operating income −14 −19 −44 −84 −127
Net income −14 −19 −46 −83 −123
Diluted EPS −$6.33 −$7.56 −$2.76 −$2.07 −$3.03
Growth (year on year)
Revenue — +132.0% −75.4% −100.0% —
Margins
EBITDA margin −641.2% −391.0% <−999% — —
Operating margin −662.0% −400.0% <−999% — —
Net margin −664.3% −401.2% <−999% — —
Free-cash-flow margin −669.7% −304.5% <−999% — —
Cash flow
Cash from operations −13 −14 −38 −68 −89
Capital spending 1 0 0 1 1
Free cash flow −14 −15 −38 −69 −91
Stock-based pay 0 0 5 14 24
Free cash flow after stock pay −14 −15 −44 −83 −114
Balance sheet
Cash 8 9 434 364 49
Total debt 0 5 — 0 11
Net debt (negative = net cash) −8 −4 −434 −364 −38
Diluted shares 3m 3m 18m 40m 41m
Returned to shareholders
Buybacks 0 — — — —
Total returned 0 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+63.0%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ALXO LGVN DARE STTK RNAC MNOV Median
Revenue, last 12 months $1m $1m $1m $1m $1m $920481 $55m
Revenue growth, last 12 months — −42.7% >999% −66.6% 44.0% 875.7% 12.6%
Revenue growth, 3-year average — 10.4% — 5.2% −68.8% — 13.7%
Revenue growth, latest quarter −100.0% −9.2% 499.6% −66.6% −100.0% 240.6% 10.2%
Gross margin — 69.8% — — — 100.0% 82.9%
Operating margin <−999% <−999% −813.4% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average — <−999% >999% <−999% <−999% −905.8% −363.5%
Net margin <−999% <−999% −804.4% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% −826.8% <−999% <−999% −989.7% −168.8%
Free-cash-flow margin <−999% <−999% −860.6% <−999% <−999% −991.2% −168.1%
Free-cash-flow margin, 3-year average — <−999% >999% <−999% <−999% <−999% −310.0%
Stock pay / revenue 459.9% 132.8% 110.0% 853.2% 625.6% 100.3% 20.7%
Change in share count 63.0% — 62.5% 15.3% 143.3% 0.2% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$219M
Institutions reporting
94
Shares held vs prior quarter
▲ 12.4%
Positions opened / closed
37 / 11

Top buyers and sellers, Q2 2026: 66 institutions bought and 21 sold ; the biggest buyer was Blackrock, Inc (+7.0M shares) and the biggest seller Tcg Crossover Management, LLC (−7.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $26.9M 13.0M 12.3% 0.0%
Venbio Partners LLC $26.7M 12.9M 12.2% 0.0%
Blackrock, Inc. $15.3M 7.4M 7.0% ▲ 1552.4%
Redmile Group, LLC $15.3M 7.4M 7.0% ▼ 7.2%
Blackstone Inc. $13.6M 6.6M 6.2% ▲ 13.2%
Driehaus Capital Management LLC $12.5M 6.0M 5.7% ▲ 5.1%
Silverarc Capital Management, LLC $11.9M 5.7M 5.4% New
Tcg Crossover Management, LLC $11.7M 5.7M 5.3% ▼ 56.5%
Vanguard Capital Management LLC $10.3M 5.0M 4.7% ▲ 19.0%
Vivo Capital, LLC $6.6M 3.2M 3.0% 0.0%
Marshall Wace, LLP $6.4M 3.1M 2.9% ▼ 18.3%
5Am Venture Management, LLC $6.3M 3.1M 2.9% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not ALX Oncology Holdings Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $5M 1 trade by 1 insider, last 12 months Insider sales History → $42,588 7 trades by 3 insiders · 0% under pre-set plans
Net ▲ $5M net buying
Insider Date Trade Shares Price Value
Wong Shelly SVP, FINANCE AND CAO August 17, 2026 Sell 573 $1.93 $1,106
Lettmann Jason CHIEF EXECUTIVE OFFICER August 17, 2026 Sell 2,230 $1.93 $4,304
Wong Shelly SVP, FINANCE AND CAO July 1, 2026 Sell 1,404 $2.04 $2,864
Pinto Shelly SVP, FINANCE AND CAO March 19, 2026 Sell 903 $2.17 $1,960
Lettmann Jason CHIEF EXECUTIVE OFFICER March 19, 2026 Sell 12,311 $2.17 $26,715
Pinto Shelly SVP, FINANCE AND CAO February 18, 2026 Sell 565 $2.27 $1,283
Goodman Corey S Director February 2, 2026 Buy 3,184,713 $1.57 $5M
Pinto Shelly SVP, FINANCE AND CAO January 6, 2026 Sell 3,925 $1.11 $4,357

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 6, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 8, 2026
  • February 27, 2026
  • November 7, 2025
  • August 12, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on ALX Oncology Holdings Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

ALX Oncology Holdings Inc in brief

What does ALX Oncology Holdings Inc do?
ALX Oncology Holdings Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is ALX Oncology Holdings Inc's stock ticker?
ALX Oncology Holdings Inc trades under the ticker ALXO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are ALX Oncology Holdings Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Venbio Partners LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is ALX Oncology Holdings Inc's market cap?
On December 30, 2022, ALX Oncology Holdings Inc's market capitalisation was about $459M and net debt of -$38.2M. Market figures come from third-party market data and may be delayed.
Who are ALX Oncology Holdings Inc's competitors?
In our Biotechnology peer group, the companies closest to ALX Oncology Holdings Inc are Longeveron Inc., Dare Bioscience, Inc., Shattuck Labs, Inc., Cartesian Therapeutics, Inc. and Medicinova Inc. The side-by-side comparison below sets their revenue, margins and growth against ALX Oncology Holdings Inc's.
Are insiders buying or selling ALX Oncology Holdings Inc stock?
Over the last 12 months, ALX Oncology Holdings Inc's directors and officers reported 1 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
When is ALX Oncology Holdings Inc's next earnings date?
Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — ALX Oncology Holdings Inc announces its own schedule.